000 04296cam a2200733Ma 4500
001 ocn831464032
003 OCoLC
005 20230823095113.0
006 m o d
007 cr |n|||||||||
008 121010s2013 nju ob 001 0 eng d
040 _aAZU
_beng
_epn
_cAZU
_dOCLCO
_dCCO
_dIDEBK
_dE7B
_dGPM
_dOCLCF
_dYDXCP
_dRECBK
_dMHW
_dEBLCP
_dN$T
_dDG1
_dTEFOD
_dDEBSZ
_dUKDOC
_dLRU
_dGGVRL
_dOCLCQ
_dAU@
_dCDX
_dDEBBG
_dTEFOD
_dOCLCQ
_dCOO
_dOCLCQ
_dNKT
_dAZK
019 _a823389919
_a829353805
_a864914474
_a880910023
_a961488066
_a962624123
020 _a9781118487471
_q(pbk.)
020 _a1118487478
_q(pbk.)
020 _a9781283917421
_q(MyiLibrary)
020 _a1283917424
_q(MyiLibrary)
020 _a9781118511251
_q(electronic bk.)
020 _a1118511255
_q(electronic bk.)
020 _a9781118511299
_q(electronic bk.)
020 _a1118511298
_q(electronic bk.)
020 _a9781118511329
_q(electronic bk.)
020 _a1118511328
_q(electronic bk.)
028 0 1 _aEB00063788
_bRecorded Books
029 1 _aAU@
_b000050591439
029 1 _aAU@
_b000051955577
029 1 _aAU@
_b000052918221
029 1 _aDEBBG
_bBV040884467
029 1 _aDEBBG
_bBV041052577
029 1 _aDEBBG
_bBV041906704
029 1 _aDEBSZ
_b397453892
029 1 _aDKDLA
_b820120-katalog:000600440
029 1 _aNZ1
_b14976927
029 1 _aDEBBG
_bBV043395679
035 _a(OCoLC)831464032
_z(OCoLC)823389919
_z(OCoLC)829353805
_z(OCoLC)864914474
_z(OCoLC)880910023
_z(OCoLC)961488066
_z(OCoLC)962624123
037 _a684D5251-34C3-4198-A03A-18F445996D72
_bOverDrive, Inc.
_nhttp://www.overdrive.com
050 4 _aHD9665.5
_b.L36 2013eb
072 7 _aBUS
_x070130
_2bisacsh
082 0 4 _a338.4/76151
_223
049 _aMAIN
100 1 _aLaMattina, John L.
245 1 0 _aDevalued and Distrusted :
_bCan the Pharmaceutical Industry Restore Its Broken Image? /
_cJohn L. LaMattina, PhD.
260 _aHoboken, New Jersey :
_bWiley,
_c[2013]
300 _a1 online resource (ix, 125 pages)
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _adata file
_2rda
500 _aIncludes index.
500 _aMachine generated contents note: Introduction Part 1. "The 4 secrets that drug companies don't want you to know" part 2. What has happened to R & D productivity? a. impact of mergers b. impact of FDA c. impact of payers Part 3. Challenges in key therapeutic areas for improving health a. cancer b. diseases of the brain c. cardiovascular disease d. diabetes e. bacterial Infections part 4. Improving R & D output a. view of others b. personal vision part 5. Restoring the pharma image part 6. Final thoughts.
588 0 _aPrint version record.
520 _a"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"--
_cProvided by publisher.
504 _aIncludes bibliographical references and index.
505 0 _a1. The four secrets the drug companies don't want you to know -- 2. What has happened to R & D productivity? -- 3. Key therapeutic areas for improving health -- 4. Improving R & D output -- 5. Restoring pharma's image -- 6. Final thoughts.
650 0 _aPharmaceutical industry
_xCorrupt practices.
650 4 _aMedical.
650 7 _aMEDICAL
_xPharmacology.
_2bisacsh
650 7 _aPharmaceutical industry
_xCorrupt practices.
_2fast
_0(OCoLC)fst01060133
655 4 _aElectronic books.
776 0 8 _iPrint version:
_aLaMattina, John L.
_tDevalued and distrusted.
_dHoboken, New Jersey : John Wiley & Sons, Inc., [2013]
_z9781118487471
_w(DLC) 2012032915
_w(OCoLC)811597120
856 4 0 _uhttp://dx.doi.org/10.1002/9781118511329
_zWiley Online Library
994 _a92
_bDG1
999 _c20347
_d20306
526 _bph